Eton Pharmaceuticals, Inc.
NASDAQ:ETONBiotechnology
-$0.46 today
- Market cap
- $1.79B
- Beta
- 0.89
- P/E (TTM)
- -597.6
- EPS (TTM)
- -$0.05
Volume 0.48M
Average 0.43M
ETON Revenue
Total income from selling goods and services before any costs are deducted; the top line of the income statement.
Eton Pharmaceuticals, Inc.NASDAQ: ETON
Revenue · Q1 FY2026 · quarter ended Mar 2026
Revenue grows, but more slowly than its trailing trend
Q1 FY2026 revenue of $24.27M rose 40.4% year over year, behind the +79.9% change in trailing-twelve-month revenue. Sequentially, it rose 14.0% from the prior quarter. Over 3 fiscal years it compounded at +55.5% a year.
Context
- Revenue increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether revenue reaches the consensus estimate from 3 analysts of $179.9M (+125.0%) for the fiscal year ending Dec 2026, a step up from the +104.9% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $24.27M+14.0% QoQ
- Last fiscal yearDec 2025
- $79.95M+104.9% YoY
- LTMMar 2026
- $86.93M+79.9% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +40.4% | +43.2% | +2.8 pp |
| 1 year | +104.9% | +125.0% | +20.1 pp |
| 3-year CAGR | +55.5% | +64.6% | +9.0 pp |
| 5-year CAGR | +46.0% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Revenue history
USD · from the income statement
- Latest · FY2025
- 79.95M USD
- Year-over-year change
- +104.9%
- 4-year CAGR
- +38.3%
| Period | Period end | Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 79.95M | +104.9% |
| FY2024 | 2024-12-31 | 39.01M | +23.3% |
| FY2023 | 2023-12-31 | 31.64M | +48.9% |
| FY2022 | 2022-12-31 | 21.25M | -2.7% |
| FY2021 | 2021-12-31 | 21.83M | — |
Revenue vs competitors
How ETON compares with its peers on the latest reported figures
- ETON's LTM Mar 2026 revenue of $86.93M is the 6th highest of the 10 companies compared; the peer median is $122.29M.
- Its year-over-year change of +79.9% is the 3rd highest of 8, against a peer median of +49.4%.
- Over three fiscal years its annual growth of +55.5% compares with a peer median of +64.9%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Sep 2026 | $959.76M | -0.7% | +17.1% | |
| LTM Mar 2026 | $669.43M | +13.3% | +22.8% | |
| LTM Sep 2026 | $651.04M | +49.4% | +64.9% | |
| LTM Mar 2026 | $369.38M | +15.2% | +22.4% | |
| LTM Mar 2026 | $122.29M | +201.3% | +118.8% | |
| LTM Mar 2026 | $86.93M | +79.9% | +55.5% | |
| LTM Mar 2026 | $69.64M | +123.1% | +610.3% | |
| LTM Mar 2026 | $51M | +65.0% | +207.5% | |
| LTM Mar 2026 | $0 | — | — | |
| LTM Mar 2026 | $0 | — | — | |
| Peer median (excluding ETON) | $122.29M | +49.4% | +64.9% | |
Competitors are the stored peer set for ETON. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 21.83M | 21.25M | 31.64M | 39.01M | 79.95M |
| Cost of Revenue | 2.62M | 6.93M | 10.58M | 15.6M | 37.21M |
| Gross Profit | 19.21M | 14.32M | 21.06M | 23.41M | 42.74M |
| Gross Margin | 88.0% | 67.4% | 66.6% | 60.0% | 53.5% |
| Research & Development | 6.24M | 4M | 3.32M | 3.26M | 7.77M |
| Selling, General & Admin | 14.47M | 18.58M | 18.93M | 22.75M | 35.82M |
| Operating Expenses | 20.7M | 22.58M | 22.25M | 26.01M | 42.67M |
| Depreciation & Amortization | 462K | 1.77M | 901K | 1.15M | 4.04M |
| EBITDA | (1.49M) | (7.25M) | 212K | (657K) | 4.27M |
| EBITDA Margin | -6.8% | -34.1% | 0.7% | -1.7% | 5.3% |
| Operating Income | (1.5M) | (8.26M) | (1.19M) | (2.6M) | 72K |
| Operating Margin | -6.8% | -38.9% | -3.8% | -6.7% | 0.1% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 1.04M | 955K | 1.06M | 2.01M | 4.78M |
| Other Income / Expenses | (460K) | (761K) | 503K | (1.21M) | (4.63M) |
| Income Before Tax | (1.96M) | (9.02M) | (689K) | (3.81M) | (4.56M) |
| Pre-Tax Margin | -9.0% | -42.4% | -2.2% | -9.8% | -5.7% |
| Income Tax Expense | 0 | 0 | 247K | 15K | 43K |
| Net Income | (1.96M) | (9.02M) | (936K) | (3.82M) | (4.6M) |
| Net Margin | -9.0% | -42.4% | -3.0% | -9.8% | -5.8% |
| EPS (Basic) | (0.08) | (0.36) | (0.04) | (0.15) | (0.17) |
| EPS (Diluted) | (0.08) | (0.36) | (0.04) | (0.15) | (0.17) |
| Weighted Avg Shares | 25.21M | 25.15M | 25.65M | 25.9M | 26.91M |
| Weighted Avg Shares (Diluted) | 25.21M | 25.15M | 25.65M | 25.9M | 26.91M |
Eton Pharmaceuticals, Inc.
NASDAQ:ETON
Intrinsic Alpha fair value
Locked
Current Price
$61.99
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.